<DOC>
	<DOCNO>NCT01824459</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment Advanced Recurrent Diffuse Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Patients .</brief_summary>
	<brief_title>S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment Advanced Recurrent Diffuse Gastric Adenocarcinoma Patients</brief_title>
	<detailed_description>The primary endpoint Overall survival time ( OS ) .Secondary overall response rate ( ORR ) , time treatment failure ( TTF ) , treatment progression time ( TTP ) adverse reaction two group ( AE ) . Study design : This prospective randomize control study . Sample size : This non-inferior study . The planned sample size 446 patient , allow 5 % dropout rate assume 1-year median overall survival 55 % hazard ratio 1.33 , α=0.05 , β=0.2 . The plan enrol time 24 month 3 year follow .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. histologically confirm unresectable advanced recurrent diffusetype gastric adenocarcinoma gastroesophageal junction adenocarcinoma . 2 . 18 year old 75 year old , able conduct oral administration . 3 . Measurable disease , accord Response Evaluation Criteria Solid Tumours ( RECIST 1.1 ) ，except nonmeasurable evaluable disease , peritoneal metastasis 4 . No palliative chemotherapy radiotherapy . Previous adjuvant neoadjuvant chemotherapy , applicable , 12 month . 5 . ECOG systemic status score 0 2 . 6. normal organ function , meet follow criterion : 1 . ALT AST ( ≤2.5 time ULN ( ≤5 time ULN patient liver metastasis ) 2 . ALP ≤ 2 time ULN ; ( patient liver metastasis limit ALP ) . 3 . Total bilirubin ≤ 1 time ULN . 4 . Absolute neutrophil count ≥ 2.0 × 10^9 / L. 5 . Platelet count ≥ 100 × 10^9 / L. 6 . Hemoglobin ≥ 80g / L. 7 . Creatinine ≤ 1.25 time ULN . 8 . The estimated creatinine clearance ≥ 60 mL/min ( CockcroftGault formula ) . 7 . Signed informed consent , treatment , followup inspection accordance study protocol . 8 . Life expectancy great 3 month . 9 . At least 3 week major surgery . 1 . Previous adjuvant neoadjuvant chemotherapy within prescribed time 2. investigator determines patient suitable participation study , specifically include ( limited ) : 1 . The past five year malignancy , appropriate treatment cervical carcinoma situ nonmelanoma skin cancer . 2. brain metastasis leptomeningeal metastasis . 3. myocardial infarction ( within past six month ) , severe unstable angina , congestive heart failure . 4 . Serious complication ( include paralytic ileus , intestinal obstruction , interstitial pneumonia , lung fibrosis , beyond control diabetes , renal insufficiency cirrhosis liver , etc. ) . 5 . Chronic nausea , vomit , diarrhea ( per day great equal 4 time watery stool ) . 6 . Gastrointestinal bleeding , need frequent blood transfusion . 7. human immunodeficiency virus ( HIV ) carrier suffer AIDS ( AIDS ) . 8 . Suffering mental illness . 9. neuropathy severity ≥grade 2 . 10 . Infectious disease inflammation , body temperature ≥ 38 ℃ . 3 . Cisplatin , oxaliplatin , S1 allergy . 4 . Pregnancy breastfeed woman . 5. refuse take appropriate contraceptive measure ( include male patient ) . 6 . Under experimental drug within 4 week . 7 . Under anticancer treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diffuse-type gastric cancer</keyword>
	<keyword>Advance Gastric Cancer</keyword>
	<keyword>Recurrent Gastric Cancer</keyword>
	<keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
	<keyword>SOX , S-1+Oxaliplatin</keyword>
	<keyword>OS ,</keyword>
	<keyword>ORR ,</keyword>
	<keyword>TTP ,</keyword>
	<keyword>TTF ,</keyword>
	<keyword>safety</keyword>
</DOC>